Douglas S. Ingram


One of Doug’s earliest jobs was as a disc jockey. It was clearly not his calling, but he fully embraced the Saturday Night fever vibe required.

Doug brings to Relay Therapeutics a wealth of experience, having spent more than 20 years in executive and operational roles across the biotech and pharma industry.

Doug has been president and chief executive officer of Sarepta Therapeutics since 2017, and also serves as a member of the company’s board of directors. Prior to Sarepta, he served as the president, CEO and director of Chase Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company. Prior to joining Chase Pharmaceuticals, Doug was at Allergan, Inc. from 2001, serving as the company’s president from 2013 until Allergan’s acquisition by Actavis in 2015 for $66 billion. There, he also previously served in various roles including president, Europe, Africa and Middle East; chief administrative officer; and general counsel.

Doug holds a J.D. from the University of Arizona and a B.S. from Arizona State University.